Table. 3.

Table. 3.

Comparison of success rates (%) summarized

Total N Success N (%) Total N Success N (%) P-value
In patients treated with PIPC/TAZ
Treated with IVIG 26 14 (53.8) Treated without IVIG 22 11 (50.0) 1.000
In patients treated with MEPM
Treated with IVIG 13 7 (53.8) Treated without IVIG 23 10 (43.5) 0.730
In patients treated with IVIG
Treated with PIPC/TAZ 26 14 (53.8) Treated with MEPM 13 7 (53.8) 1.000
In patients treated without IVIG
Treated with PIPC/TAZ 22 11 (50.0) Treated with MEPM 23 10 (43.5) 0.768
In all patients
Treated with IVIG 39 21 (53.8) Treated without IVIG 45 21 (46.7) 0.662
In patients with serum IgG lower than 500 mg/dL
Treated with IVIG 8 4 (50.0) Treated without IVIG 10 5 (50.0) 1.000
In patients with serum IgG higher than 500 mg/dL
Treated with IVIG 31 17 (54.8) Treated without IVIG 35 16 (45.7) 0.622
In patients younger than 8 years
Treated with IVIG 14 11 (78.6) Treated without IVIG 14 6 (42.9) 0.120
In patients aged 8 years and older
Treated with IVIG 25 10 (40.0) Treated without IVIG 31 15 (48.4) 0.596
In patients treated with IVIG
Younger than 8 years 14 11 (78.6) Aged 8 years and older 25 10 (40.0) 0.043
In patients treated without IVIG
Younger than 8 years 14 6 (42.9) Aged 8 years and older 31 15 (48.4) 0.759

PIPC/TAZ, piperacillin tazobactam; IVIG, intravenous immunoglobulin; MEPM, meropenem; IgG, immunoglobulin G.

Clin Pediatr Hematol Oncol 2021;28:75-83
© 2021 Clin Pediatr Hematol Oncol